NO874040L - Behandlet lipidregulator. - Google Patents

Behandlet lipidregulator.

Info

Publication number: NO874040L
Authority: NO; Norway
Prior art keywords: cholestyramine; lipid; approx; gemfibrozil; resin
Prior art date: 1986-09-26

Application number

NO874040A

Other languages

English (en)

Norwegian (no)

Other versions

NO874040D0 (no

Inventor

Isaac Ghebre-Sellassie

Robert H Gordon

Mahdi B Fawzi

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-09-26

Filing date

1987-09-25

Publication date

1988-03-28

1987-09-25 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1987-09-25 Publication of NO874040D0 publication Critical patent/NO874040D0/no

1988-03-28 Publication of NO874040L publication Critical patent/NO874040L/no

Links

150000002632 lipids Chemical class 0.000 title claims description 18
229920001268 Cholestyramine Polymers 0.000 claims description 31
238000002360 preparation method Methods 0.000 claims description 20
229940079593 drug Drugs 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 18
238000000576 coating method Methods 0.000 claims description 14
239000011248 coating agent Substances 0.000 claims description 13
238000000034 method Methods 0.000 claims description 10
239000008187 granular material Substances 0.000 claims description 7
229940107170 cholestyramine resin Drugs 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
239000003741 agents affecting lipid metabolism Substances 0.000 claims description 2
239000002702 enteric coating Substances 0.000 claims description 2
238000009505 enteric coating Methods 0.000 claims description 2
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 20
229960003627 gemfibrozil Drugs 0.000 description 20
239000000463 material Substances 0.000 description 19
239000011347 resin Substances 0.000 description 12
229920005989 resin Polymers 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 8
210000000936 intestine Anatomy 0.000 description 7
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
235000009508 confectionery Nutrition 0.000 description 6
238000005469 granulation Methods 0.000 description 6
230000003179 granulation Effects 0.000 description 6
229940030627 lipid modifying agent Drugs 0.000 description 6
239000000126 substance Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
230000009286 beneficial effect Effects 0.000 description 5
239000003613 bile acid Substances 0.000 description 5
239000003833 bile salt Substances 0.000 description 5
229940112822 chewing gum Drugs 0.000 description 5
235000015218 chewing gum Nutrition 0.000 description 5
239000000047 product Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000003524 antilipemic agent Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000003607 modifier Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
229940093761 bile salts Drugs 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000000890 drug combination Substances 0.000 description 3
210000003608 fece Anatomy 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000003957 anion exchange resin Substances 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000000872 buffer Substances 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
238000013461 design Methods 0.000 description 2
210000001198 duodenum Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229940125753 fibrate Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000011707 mineral Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
235000010603 pastilles Nutrition 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
-1 shower systems Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
WFXURHIXPXVPGM-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 WFXURHIXPXVPGM-UHFFFAOYSA-N 0.000 description 1
ZZYHCCDMBJTROG-UHFFFAOYSA-N 2-(2-benzylphenoxy)ethyl-dimethylazanium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O.C[NH+](C)CCOC1=CC=CC=C1CC1=CC=CC=C1 ZZYHCCDMBJTROG-UHFFFAOYSA-N 0.000 description 1
ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
239000006057 Non-nutritive feed additive Substances 0.000 description 1
DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000004063 acid-resistant material Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940098391 carbetapentane citrate Drugs 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
229960003291 chlorphenamine Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229960002174 ciprofibrate Drugs 0.000 description 1
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229960004415 codeine phosphate Drugs 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
OJBNDADUQQUPLL-UHFFFAOYSA-N colestipol hydrochloride Chemical compound Cl.ClCC1CO1.NCCNCCN OJBNDADUQQUPLL-UHFFFAOYSA-N 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
229960001767 dextrothyroxine Drugs 0.000 description 1
229960000559 dextrothyroxine sodium Drugs 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229960005008 doxylamine succinate Drugs 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000010235 enterohepatic circulation Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
229960002737 fructose Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
235000020786 mineral supplement Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
229960004708 noscapine Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940096714 other lipid modifying agent in atc Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229960003956 phenindamine tartrate Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
229960002254 phenyltoloxamine citrate Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
229940018203 pyrilamine maleate Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1
229960005080 warfarin Drugs 0.000 description 1
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Confectionery (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO874040A 1986-09-26 1987-09-25 Behandlet lipidregulator. NO874040L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US91290286A	1986-09-26	1986-09-26

Publications (2)

Publication Number	Publication Date
NO874040D0 NO874040D0 (no)	1987-09-25
NO874040L true NO874040L (no)	1988-03-28

Family

ID=25432663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO874040A NO874040L (no)	1986-09-26	1987-09-25	Behandlet lipidregulator.

Country Status (10)

Country	Link
EP (1)	EP0261693A1 (fi)
JP (1)	JPS63152321A (fi)
KR (1)	KR880003628A (fi)
AU (1)	AU7894887A (fi)
DK (1)	DK504187A (fi)
FI (1)	FI874164L (fi)
IE (1)	IE872589L (fi)
NO (1)	NO874040L (fi)
PT (1)	PT85775B (fi)
ZA (1)	ZA876640B (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5372823A (en) *	1989-03-16	1994-12-13	Bristol-Myers Squibb Company	Direct compression cholestyramine tablet and solvent-free coating thereof
US4956182A (en) *	1989-03-16	1990-09-11	Bristol-Myers Company	Direct compression cholestyramine tablet and solvent-free coating therefor
EP0409432A3 (en) *	1989-07-20	1991-12-11	Warner-Lambert Company	Confectionery delivery system
IL95574A (en)	1989-09-09	1994-11-11	Knoll Ag	Colestyramine preparation
EP0447362A1 (en) *	1990-03-13	1991-09-18	Warner-Lambert Company	Improved ingestible anion exchange resin delivery system compositions containing adipic acid
EP0462067A1 (en) *	1990-06-15	1991-12-18	Warner-Lambert Company	Gemfibrozil formulations
EP0731693A1 (en) *	1993-12-08	1996-09-18	Vitaphore Corporation	Microsphere drug delivery system
TWI241195B (en) *	2000-04-10	2005-10-11	Shionogi & Co	Preventive agent for bile acidic diarrhea
PE20180690A1 (es)	2015-04-27	2018-04-23	Intercept Pharmaceuticals Inc	Composiciones de acido obeticolico y metodos de uso

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH556154A (fr) *	1972-09-05	1974-11-29	Derobert Pierre A Etablissemen	Fermoir de securite.
JPS5867616A (ja) *	1981-10-15	1983-04-22	Tanabe Seiyaku Co Ltd	腸溶性マイクロカプセル
CA1265785A (en) *	1984-06-04	1990-02-13	Kumi Yoshida	Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them

1987
- 1987-09-04 ZA ZA876640A patent/ZA876640B/xx unknown
- 1987-09-23 FI FI874164A patent/FI874164L/fi not_active Application Discontinuation
- 1987-09-23 PT PT85775A patent/PT85775B/pt not_active IP Right Cessation
- 1987-09-24 AU AU78948/87A patent/AU7894887A/en not_active Abandoned
- 1987-09-25 EP EP87114072A patent/EP0261693A1/en not_active Withdrawn
- 1987-09-25 IE IE872589A patent/IE872589L/xx unknown
- 1987-09-25 NO NO874040A patent/NO874040L/no unknown
- 1987-09-25 JP JP62239093A patent/JPS63152321A/ja active Pending
- 1987-09-25 DK DK504187A patent/DK504187A/da not_active Application Discontinuation
- 1987-09-26 KR KR870010697A patent/KR880003628A/ko not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU7894887A (en)	1988-03-31
DK504187D0 (da)	1987-09-25
IE872589L (en)	1988-03-26
FI874164L (fi)	1988-03-27
JPS63152321A (ja)	1988-06-24
DK504187A (da)	1988-03-27
ZA876640B (en)	1988-03-08
NO874040D0 (no)	1987-09-25
KR880003628A (ko)	1988-05-28
FI874164A0 (fi)	1987-09-23
EP0261693A1 (en)	1988-03-30
PT85775B (pt)	1990-07-31
PT85775A (en)	1987-10-01

Publication	Publication Date	Title
US4814354A (en)	1989-03-21	Lipid regulating agents
KR100201767B1 (ko)	1999-06-15	혈장 약물 농도의 신속한 초기 증가량을 시현하는 24시간 경구용 오피오이드 제형을 투여함으로써 통증을 치료하는 방법
US4221778A (en)	1980-09-09	Prolonged release pharmaceutical preparations
JPS62298533A (ja)	1987-12-25	高コレステロ−ル血症治療薬およびその製造方法
PT85353B (pt)	1990-04-30	Processo de preparacao de composicoes farmaceuticas de libertacao controlada e de matriz a base de alcool alifatico e resina acrilica
WO2000013672A1 (en)	2000-03-16	New solid dose form of nanoparticulate naproxen
WO2001008661A2 (en)	2001-02-08	Opioid sustained-released formulation
HU218673B (hu)	2000-10-28	Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
JPH0157086B2 (fi)	1989-12-04
SE453797B (sv)	1988-03-07	Terapeutisk, solid enhetsdoseringsform med forlengt utlosningsmonster vars berarmaterial innehaller hydroxypropylmetylcellulosa med hog molekyler vikt
US20130028969A1 (en)	2013-01-31	Method for stable and controlled delivery of (-)-hydroxycitric acid
JPS62501845A (ja)	1987-07-23	制御放出塩化カリウム
IE922365A1 (en)	1992-11-18	Improved oral dosing formulations of dideoxy purine¹nucleosides
NO874040L (no)	1988-03-28	Behandlet lipidregulator.
WO1997033574A1 (fr)	1997-09-18	Comprimes a liberation prolongee a base de valproate metallique
CA2645574C (en)	2012-03-13	A medicine used for curing hyperphosphatemia and its preparation method
JPH0733682A (ja)	1995-02-03	新規複合体、それを担体として利用する徐放性製剤
JPH07507293A (ja)	1995-08-10	ヒスタミンｈ↓２−受容体アンタゴニストおよび陽イオン交換体複合体による組成物
US20130150448A1 (en)	2013-06-13	Dimeric double metal salts of (-) hydroxycitric acid, methods of making and uses of same
RU2209087C2 (ru)	2003-07-27	Агент для пролонгирования действия лекарственного препарата и лекарственная композиция на его основе
WO2008140444A1 (en)	2008-11-20	Dimeric double metal salts of(-) hydroxycitric acid, methods of making and uses of same
JP2964195B2 (ja)	1999-10-18	ピロキシカム錠及びその製造法
JPH11228449A (ja)	1999-08-24	薬剤用徐放化剤及びそれを含有した徐放性医薬組成物
JP4867128B2 (ja)	2012-02-01	経口鼻炎治療用組成物
CN101062047B (zh)	2010-06-09	一种含有异甘草酸和苦参素的组合物及其用途